Skip to content

Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016
121.40 -2.62 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170
    Market Newswire · 2026/8/31
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182
    Market Newswire · 2026/9/1
  • BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $190
    Market Newswire · 2026/11/11
  • Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173
    Market Newswire · 2026/11/10
  • Rating change
    BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178
    Market Newswire · 2026/8/17
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186
    Market Newswire · 2026/8/11
  • UBS Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $184
    Market Newswire · 2026/11/10
  • Rating change
    Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $180
    Market Newswire · 2026/11/6
  • Rating change
    UBS Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $184
    Market Newswire · 2026/10/12
  • Rating change
    J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149
    Market Newswire · 2026/9/1
  • Rating change
    Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
    Market Newswire · 2026/9/2
  • Rating change
    Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182
    Market Newswire · 2026/10/15
  • Rating change
    H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170
    Market Newswire · 2026/9/1
  • Rating change
    BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $190
    Market Newswire · 2026/11/6
  • H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $221
    Market Newswire · 2026/11/6
  • Rating change
    TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $160
    Market Newswire · 2026/10/21
  • Rating change
    Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186
    Market Newswire · 2026/9/1
  • Rating change
    J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149
    Market Newswire · 2026/8/13
  • Rating change
    BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178
    Market Newswire · 2026/8/31
  • J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $151
    Market Newswire · 2026/11/9
  • Rating change
    Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173
    Market Newswire · 2026/8/31
  • Barclays Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $180
    Market Newswire · 2026/10/13
  • Rating change
    Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186
    Market Newswire · 2026/8/10
  • Rating change
    Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $173
    Market Newswire · 2026/8/10
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175
    Market Newswire · 2026/8/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Protagonist Therapeutics discussion 0 comments

Add a comment